LA JOLLA PHARMACEUTICAL CO
Form 3
August 04, 2014

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â TANG KEVIN C
(Last) (First) (Middle)

4747 EXECUTIVE DRIVE,Â SUITE 510
(Street)

SAN DIEGO,Â CAÂ 92121
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/23/2014

3. Issuer Name **and** Ticker or Trading Symbol
LA JOLLA PHARMACEUTICAL CO [LJPC]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,699,067	I (1)	By LP (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title			

		Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Series C-1(2) Convertible Preferred Stock	01/19/2012 (2)	Â (3)	Common Stock	6,167,289	$ (4)	I (1)	By LP (1)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TANG KEVIN C 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO,Â CAÂ 92121	Â	Â	Â	Â
TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO,Â CAÂ 92121	Â	Â	Â	Â
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE SUITE 510 SAN DIEGO,Â CAÂ 92121	Â	Â	Â	Â

Signatures

/s/ Kevin C. Tang	08/04/2014
**Signature of Reporting Person	Date
/s/ Kevin C. Tang, Managing Member	08/04/2014
**Signature of Reporting Person	Date
/s/ Kevin C. Tang, Managing Member of Tang Capital Management LLC, General Partner	08/04/2014
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

(2) The Series C-1(2) Convertible Preferred Stock (the "Series C Stock") can only be converted into Common Stock to the extent that, after such conversion, the holder would beneficially own no more than 9.999% of the issuer's Common Stock. As such, none of the Series C Stock reported herein is currently convertible into the issuer's Common Stock.

(3) The Series C Stock has no expiration date.

(4) Each share of Series C Stock is convertible into the issuer's Common Stock at a rate of 1,724 shares of Common Stock for each share of Series C Stock tendered for conversion.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.